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ABSTRACT
Background: Cardiac syndrome X (CSX) is a condition in which patients have the pain of angina despite 
normal coronary angiogram. Recently, Helicobacter pylori (H. pylori) bacteria has been associated with 
CSX. However, there is no obvious data about the frequency of its virulent strain (cytotoxine associated gene 
A: CagA) in patients with CSX. We surveyed the frequency of H. pylori and CagA antibodies in patients with 
cardiac syndrome X and healthy controls. Materials and Methods: Plasma samples from 100 CSX patients 
(61 females and 39 males; mean age: 51.8 ± 12.3 years) and 100 healthy controls (61 females and 39 males; 
mean age: 48.9 ± 6.3 years) were tested for the presence of IgG antibody to H. pylori using enzyme linked 
immunosorbent assay (ELISA) method. Also, infected patients were determined by the presence of IgG antibody 
to CagA by ELISA method. Statistical analysis was carried out using chi-square test and independent samples 
T-test. Results: Ninety two percent (92/100) of patients were anti-H. pylori positive (anti-H. pylori+), while 
only 56.0% (56/100) of control group were anti-H. pylori+ (P<0.01). However, prevalence of anti-CagA positive 
(anti- CagA+) in H. pylori infected- CSX patients and control groups were 59.8% (55/92) and 60.7% (34/56), 
respectively (P >0.05). Conclusion: Thus, due to the high frequency of anti-H. pylori in CSX patients, and the 
probable causative effect of chronic infection in vascular diseases, it is suggested that H. pylori has a probable 
role in the pathogenesis of CSX.
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of the extensive studies.[4] Previous studies had shown 
an association between viral and bacterial infections with 
vascular diseases, such as ischemic heart disease and CSX.[5] 
Helicobacter pylori (H. pylori) is a gram-negative bacterium 
that causes various extra-digestive diseases, including 
functional vascular disorders such as primary migraine 
and primary Raynaud’s phenomenon, as well as ischemic 
heart disease.[5,6] An inflammatory response possibly due to   
H. pylori has been proposed as a mechanism in patients with 
coronary artery disease (CAD). In addition, H. pylori has 
been recently also associated with ischemic heart disease 
and CSX.[2,3,7,8] H. pylori strains may be divided into at least 
two subgroups based on the expression or nonexpression 
of cytotoxin-associated gene A (CagA) and the vacuolating 
cytotoxin.[9,10] The CagA has been identified as a possible 
marker of H. pylori virulence.[11,12]
Original Article
INTRODUCTION
Cardiac syndrome X (CSX) is defined by a typical angina 
like chest pain without flow-limiting stenoses on coronary 
angiography and exclusion of noncardiac chest pain.[1] There 
is no obvious etiology for this syndrome.[2] One to 12% of 
individuals with myocardial infarction who undergo coronary 
angiography are found to have normal coronary arteries.[3] 
The pathogenesis of this syndrome is not well known despite 
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Our literature review did not bring up any obvious data 
about the frequency of CagA in patients with CSX. Hence, 
this study was designed to determine the frequency of 
anti-H. pylori and anti-CagA status in CSX patients.
MATERIALS AND METHODS
Study design
Patients with CSX and apparently healthy controls were 
studied. The CSX group consisted of 100 consecutive 
patients. Entry criteria were typical anginal chest pain, 
normal 12-lead electrocardiography (ECGs) at rest, a 
positive exercise ECG stress test response and normal 
coronary angiogram. Non-cardiac causes of chest pain 
such as gastrointestinal and musculoskeletal disorders were 
also investigated and ruled out as appropriate. Patients with 
diabetes mellitus were not included, as inflammatory marker 
levels increase in diabetes mellitus. A questionnaire was 
administrated to obtain general information regarding age, 
sex, body mass index (BMI), systolic and diastolic blood 
pressures. The control group consisted of 100 apparently 
healthy subjects. None of the control individuals had a 
previous history of chest pain or acute/chronic diseases. 
Also, none of these subjects were taking cardiac or non-
cardiac medications. The study was approved by Medical 
Ethics Committee at Urmia University of Medical Sciences, 
Urmia, Iran; and all subjects gave written informed consent.
Laboratory assays
A 5-ml tri_sodium citrated blood sample was obtained 
from each subject and centrifuged at 2000 g for 15 
minutes. Plasma was aliquoted and stored at -80°C until 
analysis. Specific anti-H. pylori immunoglobulin-G (IgG) 
positivity was determined with a commercial enzyme-linked 
immunosorbent assay (ELISA) kit (Glob anti-H. pylori/IgG, 
Milan, Italy) according to the manufacturer’s instructions 
(sensitivity 96.5% and specificity 98.6%). Also, plasma 
positivity to the antigen CagA was assessed by ELISA 
(Dia.Pro, Milan, Italy; sensitivity and specificity   >98%) in 
anti-H. pylori positive (anti-H. pylori+) samples.
Statistical analysis
The data were analyzed by Statistical Package for Social 
Sciences (SPSS) 16.0 software. Age, systolic blood pressure, 
diastolic blood pressure and BMI were shown as mean ± 
standard deviation (SD). Statistical analysis was carried 
out using chi-square test and independent samples T-test. 
P value of < 0.05 was considered statistically significant.
RESULTS
One hundred CSX patients (61 females and 39 males) were 
compared with 100 age and sex matched healthy controls 
(61 females and 39 males). Demographic and clinical 
characteristics of both groups are depicted in Table 1.
As shown in Table 2, anti- H. pylori+ was diagnosed in   
92 (92.0%) patients with CSX and 56 (56.0%) individuals 
in control group (P < 0.01). Also, among CSX group,   
55 patients were positive for anti- CagA (anti- CagA+) 
(55/92: 59.8% of anti- H. pylori+) while only 34 individuals 
in control group were anti- CagA+ (34/56: 60.7% of   
anti- H. pylori+ samples, P > 0.05).
DISCUSSION
Coronary endothelial dysfunction has been proposed 
as pathogenetic mechanism in CSX.[1,13,14] 
The mechanisms responsible for endothelial dysfunction 
in CSX patients are not well understood;[15] however, some 
risk factors of CAD such as obesity, hypertension, hyper-
cholesterolaemia and smoking, are frequently present in 
Table 1: Demographic and clinical characteristics of cardiac syndrome X patients and control group
CSX Control P value
Age (years) 51.8 ± 12.3 48.9 ± 6.3 > 0.05
Sex (female/male) 61/39 61/39 > 0.05
Systolic BP (mmHg) 122.5 ± 9.3 120.2 ± 7.0 > 0.05
Diastolic BP (mmHg) 77.6 ± 8.5 75.8 ± 6.9 > 0.05
BMI (kg/m2) 26.7 ± 4.6 26.2 ± 3.2 > 0.05
BP: Blood pressure, BMI: Body mass index, CSX: Cardiac syndrome X
Table 2: Frequency of anti- H. pylori and anti-CagA status in cardiac syndrome X patients and control group
Infection Status CSX Control P value
Anti-H. pylori+ /Total 92/100 (92.0) 56/100 (56.0) < 0.01
Anti-CagA+/anti-H. pylori+ 55/92 (59.8) 34/56 (60.7) > 0.05
H. pylori: Helicobacter pylori; CagA: Cytotoxin-associated gene A, Figures in parentheses are in percentage, CSX: Cardiac syndrome X 21 Journal of Cardiovascular Disease Research Vol. 3 / No 1
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these patients and may have roles.[16] Also, previous studies 
have suggested that chronic inflammation may contribute to 
endothelial dysfunction in CSX. Lanza et al., showed that two 
indexes of systemic inflammation, C-reactive protein and 
interleukin-1 receptor antagonist, increased in patients with 
CSX compared with well-matched healthy control subjects. 
Thus, this result suggested that low-grade inflammation may 
play a pathogenetic role in CSX patients.[7]
Recent studies have suggested a possible association of 
viral and bacterial infections such as H. pylori infection in 
the etiology of acute coronary syndromes in patients with 
CAD.[17] Endothelial injury due to circulating endotoxin, 
autoimmunity with cross-reactivity of bacterial antigens 
and endothelial cells are discussed as possible underlying 
mechanisms.[3] In addition, H. pylori has been recently 
associated with CSX.[2] We speculated that H. pylori may 
also cause endothelial dysfunction directly by affecting 
the structure and function of vascular endothelial cells via 
inflammation.[18]
H. pylori may cause chronic inflammation and enhanced 
immune response due to the release of some cytotoxic 
substances which are responsible for the systemic 
manifestations of H. pylori.[19] Chronic infection of H. pylori 
most probably causes increased production of various 
inflammatory metabolites, and this could also affect blood 
vessel motility and induce endothelial dysfunction.[20] 
Epithelial cell act as the most probable target in H. pylori 
infection, and also as major interfaces between the host and 
pathogens. Thus, this interaction initiates acute mucosal 
inflammation, and interacts with the other mucosal cell 
proliferation via a cytokine network.[21] These two responses 
may be regulated differentially following induction of 
cytokines in the inflammatory cascade, including tumor 
necrosis factor-alpha and interleukin-6.[22,23]
Thus, with the results of our study, the possible role of   
H. pylori infection in the pathogenesis of CSX is suggested. 
This is the first study that shows anti- CagA status of   
H. pylori in CSX, however well designed clinical trial studies 
are needed to further confirm these results.
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